Prosecution Insights
Last updated: April 19, 2026
Application No. 18/994,418

MARINE MICROALGAL PROTEIN PREPARATIONS

Non-Final OA §103§112
Filed
Jan 14, 2025
Examiner
GWARTNEY, ELIZABETH A
Art Unit
1759
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Qualitas Health Inc.
OA Round
1 (Non-Final)
36%
Grant Probability
At Risk
1-2
OA Rounds
4y 1m
To Grant
71%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allow Rate
238 granted / 660 resolved
-28.9% vs TC avg
Strong +35% interview lift
Without
With
+35.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
59 currently pending
Career history
719
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
50.3%
+10.3% vs TC avg
§102
9.1%
-30.9% vs TC avg
§112
31.5%
-8.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 660 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 12 objected to because of the following informalities: In line 9, the phrase “(g/100 of powder)” should read “(g/100 g of powder)”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5 and 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 5, the recitation “wherein a viscosity of a solution of the protein does not increase after the liquid after heat induced gelation” renders the claim indefinite. It is not clear after what step the viscosity of the solution does not increase. Does the viscosity of the solution, a liquid, not increase after heat induced gelation? Moreover, at what concentration of protein does the solution exhibit not increase in viscosity? Regarding claim 16, the recitation “A food composition comprising the powder of claim 12, in an aqueous medium, forming an edible aqueous suspension or solution” renders the claim indefinite. It is not clear if Applicant’s intend to claim a step of “forming an edible aqueous suspension or solution” or “wherein the food composition is and edible aqueous suspension or solution.” Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 2 and 4-15 are rejected under 35 U.S.C. 103 as being unpatentable over Soto-Sierra et al. (“Process development of enzymatically-generated algal protein hydrolysates for specialty food applications”, Algal Research, 55 (2021), pp. 1-10). Regarding claims 6, 7, 11-15, Sota-Sierra et al. disclose a hydrolyzed microalgal protein product comprising 72 ± 3% (w/w) protein, 1.5% histidine, 4.8% lysine, 2.7% methionine, 6.0% phenylalanine, 6.2% threonine, 5.3% isoleucine, 9.9% leucine and 6.2% valine (i.e. essential amino acids in an amount equal to or more than 30 g/100 g-p. 8/Table 2, p. 9/Table 3) and dried (i.e., powder – p. 4/2.4.4 Purity). Sota -Sierra et al. disclose the hydrolyzed microalgal protein product has a branched-chain amino acid content (leucine, isoleucine and valine) of 21.4 g./100 g. product (p. 9/Table 3). Sota-Sierra et al. disclose the protein hydrolysates are purified from lipid-extract microalgae of Nannochloropsis sp. biomass grown in open ponds (Abstract, p. 2/2.1 Substrate preparation). While Sota-Sierra et al. disclose microalgal material from Nannochloropsis sp. biomass, the reference is silent with respect to a marine microalgal. The fact that the microalgal material from Nannochloropsis sp. biomass is obtained from a different environment, i.e., ponds v. sea, the determination of patentability is based on the claimed product and not how is was obtained. While Sota-Sierra et al. disclose a microalgal protein product comprising a protein content of 72 ± 3 g/100 g. product, the reference is silent with respect to algae residue and ash content. Given Sota-Sierra et al. disclose a microalgal protein product obtained from a lipid extracted algae of the Nannochloropsis sp. comprising protein in an amount of 72 ± 3 g/100 g. product, inherently the product would comprise algae residue. Moreover, Sota-Sierra et al. disclose a removing excess salt to a level of less than 10% by weight (i.e., ash content- p. 7-8/Section 3.2, Figure 6). While Sota-Sierra et al. does not disclose the precisely claimed amounts of the essential amino acids, a prima facie case of obviousness exists where the claimed ranges or amounts do not overlap with the prior art but are merely close (MPEP §2144.05 I). The proportions of the essential amino acids are so close that prima facie one skilled in the art would have expected them to have the same properties in a hydrolyzed protein composition intended for foodstuff. Sota-Sierra et al. is silent with respect to tryptophan. However, given Sota-Sierra et al. disclose a microalgal protein product obtained from a lipid extracted algae of the Nannochloropsis sp. and substantially similar to that presently claimed, inherently the microalgal protein product would comprise tryptophan in amount overlapping the claimed range of 0.9 to 3.1 g/100 g of powder). Sota-Sierra et al. is also silent with respect to the non-essential amino acids, alanine, arginine, asparagine + aspartic acid, cysteine, glutamine + glutamic acid, glycine, proline, serine and tyrosine. However, given Sota-Sierra et al. disclose a microalgal protein product obtained from a lipid extracted algae of the Nannochloropsis sp. substantially similar to that presently claimed, inherently the microalgal protein product would comprise the non-essential amino acids in the claimed ranges. Regarding claims 2 and 4, Sota-Sierra et al. disclose all of the claim limitations as set forth above. Sota-Sierra et al. is silent with respect to solubility of the microalgal protein product. However, given Sota-Sierra disclose a lipid extracted algae of the Nannochloropsis sp. substantially similar to that presently claimed, inherently the microalgal protein product exhibit the claimed solubility index at a pH of 7 and 3.5. Regarding claim 5, Sota-Sierra et al. disclose all of the claim limitations as set forth above. Sota-Sierra et al. is silent with respect to no viscosity change after a solution of the product has been heated. However, given Sota-Sierra disclose a lipid extracted algae of the Nannochloropsis sp. substantially similar to that presently claimed, inherently the microalgal protein product would exhibit the claimed viscosity change after a solution of the product has been heated. Regarding claim 8, Sota-Sierra et al. disclose all of the claim limitations as set forth above. While Sota-Sierra et al. disclose a microalgal protein product comprising a protein content of 72 ± 3 g/100 g. product, the reference is silent with respect to a protein content of greater than 85 g per 100 g. powder. It would have been obvious to one of ordinary skill in the art prior to the effective filing date of the present application to have modified the fractionation and depth filtration processes of Sota-Sierra et al. to make a product with higher protein concentration (i.e., increase the purity of the product). One of ordinary skill in the art would have been motivated to make a product with higher protein concentration in order to utilize the products in producing high protein foodstuff. Regarding claims 9 and 10, Sota-Sierra et al. disclose all of the claim limitations as set forth above. Sota-Sierra et al. is silent with respect to true protein digestibility and protein digestibility corrected amino acid score. However, given Sota-Sierra disclose a lipid extracted algae of the Nannochloropsis sp. substantially similar to that presently claimed, inherently the microalgal protein product would exhibit the claimed true protein digestibility and PDCAAS. Claim 3 is rejected under 35 U.S.C. 103 as being unpatentable over Soto-Sierra et al. (“Process development of enzymatically-generated algal protein hydrolysates for specialty food applications”, Algal Research, 55 (2021), pp. 1-10) as applied to claim 12, and further in view of Kadam et al. (US 2014/0242238). Regarding claim 3, Sota-Sierra et al. disclose all of the claim limitations as set forth above. While Sota-Sierra et al. disclose a microalgal protein product obtained from Nannochloropsis sp., the reference is silent with respect to Eustigmaticicae sp. Kadam et al. teach a method of extracting oil from microalgae (Abstract). Kadam et al. disclose the microalgae used for the invention are members of the class Eustigmatophyceae (i.e. Eustigmaticicae) or the genera Nannochloropsis. Given Sota-Sierra et al. disclose preparing protein from lipid-extracted microalgae of the genera Nannochloropsis, since Kadam et al. teach extracting oil from microalgae of the class Eustigmaticicae or the genera Nannochloropsis, it would have been obvious to one of ordinary skill in the art prior to the effective filing date of the present application to have used lipid-extracted microalgae of the class Eustigmaticicae as the source of microalgae in the product of Sota-Sierra et al. Claims 16-19, 25 and 26 are rejected under 35 U.S.C. 103 as being unpatentable over Soto-Sierra et al. (“Process development of enzymatically-generated algal protein hydrolysates for specialty food applications”, Algal Research, 55 (2021), pp. 1-10) as applied to claim 12, and further in view of Tang (WO 2011/057406 A1). Regarding claim 16, Sota-Sierra et al. disclose all of the claim limitations as set forth above. Sota-Sierra et al. is silent with respect to a food composition. Tang teaches a hydrolyzed microalgae protein product having a protein content of about 75% to about 90% (protein concentrate or isolate) (Abstract, [0022]-[0023]). Tang teaches the protein product is useful as a protein ingredient in nutritional beverages such as protein fortified soft drinks, sports drinks, fruit juices and other high protein drinks (p. 45/L23-27). Here, a beverage is considered an edible aqueous solution. Sota-Sierra et al. and Tang are combinable because they are concerned with the same field of endeavor, namely hydrolyzed microalgae protein products. It would have been obvious to one of ordinary skill in the art to have used the hydrolyzed microalgal protein product of Sota-Sierra et al. in a beverage, as taught by Tang to make a protein fortified beverage. Regarding claim 17, modified Sota-Sierra et al. disclose all of the claim limitations as set forth above. Tang teaches beverages, for example high protein drinks. Given the microalgal protein product of Sota-Sierra et al., a powder, would be added to the ingredients of a protein drink and mixed, inherently particles of powder would be encapsulated to some extent by the matrix of the ingredients. Regarding claim 18, modified Sota-Sierra et al. disclose all of the claim limitations as set forth above. Given Tang teaches beverages, including soft drinks, sports drink and fruit juices, inherently the juices would comprise some type of added flavor. Regarding claims 19 and 25, modified Sota-Sierra et al. disclose all of the claim limitations as set forth above. Given Tang teaches nutritional beverages such as protein fortified soft drinks, sports drinks, fruit juices and other high protein drinks, it would have been obvious to one of ordinary skill in the art prior to the effective filing date of the present invention to have adjusted, in routine processing, the protein content of a specific beverage to obtained the desired nutritional benefit while maintaining a desired sensory profile. Regarding claim 26, modified Sota-Sierra et al. disclose all of the claim limitations as set forth above. Tang et al. disclose using microalgae protein products in soft drinks (i.e., aqueous beverages having a pH less than 5- p. 45/L23-27). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELIZABETH A GWARTNEY whose telephone number is (571)270-3874. The examiner can normally be reached M-F: 9 a.m. - 5 p.m. EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Duane Smith can be reached at 571-272-1166. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ELIZABETH A. GWARTNEY Primary Examiner Art Unit 1759 /ELIZABETH GWARTNEY/Primary Examiner, Art Unit 1759
Read full office action

Prosecution Timeline

Jan 14, 2025
Application Filed
Jan 20, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12593857
FERMENTED PEA SOLUBLES
2y 5m to grant Granted Apr 07, 2026
Patent 12550925
INFANT NUTRITION WITH HYDROLYSED PROTEIN, IONIC CALCIUM AND PALMITIC ACID
2y 5m to grant Granted Feb 17, 2026
Patent 12507704
Process Recipe Cheese Product With Improved Melt And Firmness And Method For Manufacture
2y 5m to grant Granted Dec 30, 2025
Patent 12473330
METHOD FOR FRACTIONATING SOLUBLE FRACTIONS OF PEAS, FRACTION THUS OBTAINED AND UPGRADE THEREOF
2y 5m to grant Granted Nov 18, 2025
Patent 12467022
LOW-ALCOHOL BEER
2y 5m to grant Granted Nov 11, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
36%
Grant Probability
71%
With Interview (+35.0%)
4y 1m
Median Time to Grant
Low
PTA Risk
Based on 660 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month